Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how , how and . She's also tracked pharmaceutical dollars to and . Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Dr. Mehmet Oz, nominated to run the Centers for Medicare & Medicaid Services, will sell shares in Eli Lilly and UnitedHealth. Dr. Jay Bhattacharya, NIH nominee, will shed stock in Walmart and Nvidia. -
The fired staffers were tasked with making sure medications given to animals work well and are safe. -
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy of the weight-loss medicines it mailed to patients. -
Patients who bought stockpiles of alternative GLP-1 drugs online aren't sure what to do with them after learning that the compounding pharmacy that made them didn't have the right license.
-
Millions of Americans use cannabis and would like to think the products they buy are safe. But regulation is state by state and full of holes. NPR's new series digs into the risks and solutions. -
A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the agency's website, as the Trump administration halts DEI initiatives. -
RFK Jr. plans to keep collecting referral fees in lawsuits against the drug company Merck even if confirmed as HHS secretary, according to new filings with the Office of Government Ethics. -
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare. -
January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including Ozempic, drugs for HIV, cancer and many others. -
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
